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A B S T R A C T
Depression is a debilitating mental disease, characterized by persistent low mood and anhedonia. Stress re-
presents a major environmental risk factor for depression; the complex interaction of stress with genetic factors
results in different individual vulnerability or resilience to the disorder. Dysfunctions of the glutamate system
have a primary role in depression. Clinical neuroimaging studies have consistently reported alterations in vo-
lume and connectivity of cortico-limbic areas, where glutamate neurons and synapses predominate. This is
confirmed by preclinical studies in rodents, showing that repeated stress induces morphological and functional
maladaptive changes in the same brain regions altered in humans. Confirming the key role of glutamatergic
transmission in depression, compelling evidence has shown that the non-competitive NMDA receptor antagonist,
ketamine, induces, at sub-anesthetic dose, rapid and sustained antidepressant response in both humans and
rodents.
We show here that the Chronic Mild Stress model of depression induces, only in stress-vulnerable rats, de-
pressed-like anhedonic behavior, together with impairment of glutamate/GABA presynaptic release, BDNF
mRNA trafficking in dendrites and dendritic morphology in hippocampus. Moreover, we show that a single
administration of ketamine restores, in 24 h, normal behavior and most of the cellular/molecular maladaptive
changes in vulnerable rats. Interestingly, ketamine treatment did not restore BDNF mRNA levels reduced by
chronic stress but rescued dendritic trafficking of BDNF mRNA.
The present results are consistent with a mechanism of ketamine involving rapid restoration of synaptic
homeostasis, through re-equilibration of glutamate/GABA release and dendritic BDNF for synaptic translation
and reversal of synaptic and circuitry impairment.
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1. Introduction
Major depressive disorder (MDD) is a debilitating mental disease,
characterized by persistent low mood and anhedonia (loss of interest in
pleasurable activities) (American Psychiatric Association, 2013). The
etiopathogenesis of MDD is thought to involve a complex interaction of
genetic and environmental factors, among which behavioral stress is a
major one (Jaffee and Price, 2007; Uher, 2014). Indeed, especially
chronic stress exposure may induce maladaptive alterations in vulner-
able subjects, leading to increased risk of developing neuropsychiatric
disorders (Han and Nestler, 2017; McEwen, 2016; Popoli et al., 2012).
Dysfunctions of the glutamate system have been shown to have a
primary role in MDD (Duman et al., 2016; Murrough et al., 2017;
Musazzi et al., 2013; Sanacora et al., 2012). Consistently, neuroimaging
studies have reported volume and connectivity alterations in cortico-
limbic areas, including hippocampus (HPC), prefrontal cortex (PFC)
and amygdala, where glutamate neurons/synapses predominate. Pre-
clinical studies with stress-based animal models of depression have
showed atrophy/remodeling of dendrites in the same brain regions al-
tered in humans, suggesting that stress-induced maladaptive changes
have a primary role in the chain of events leading to the development of
MDD (Autry and Monteggia, 2012; Krishnan and Nestler, 2008;
McEwen, 2016; Popoli et al., 2012; Sanacora et al., 2012).
Further supporting the key role of glutamatergic transmission in
MDD, the non-competitive N-methyl-D-aspartate (NMDA) receptor an-
tagonist ketamine (KET) has been consistently reported to induce at low
sub-anesthetic dose rapid (within hours) and sustained (up to several
days) antidepressant response in both clinical and preclinical studies
(Berman et al., 2000; Kadriu et al., 2019; Zanos and Gould, 2018;
Zarate et al., 2006).
Different hypotheses on the mechanisms underlying KET anti-
depressant action have been proposed (for recent reviews, see (Kadriu
et al., 2019; Zanos and Gould, 2018)). Importantly, the behavioral ef-
fects of KET have been suggested to be related to rapid activation of
neurotrophic signaling and synaptic translation of Brain-Derived Neu-
rotrophic Factor (BDNF) (Kavalali and Monteggia, 2015, 2012;
Monteggia and Kavalali, 2013). BDNF is the main neurotrophin in the
adult brain, where it is involved in the regulation of synapse formation,
function and plasticity (Chao, 2003; Waterhouse and Xu, 2009). Dis-
inhibition of glutamate transmission by KET and the subsequent in-
crease in glutamate release activate ionotropic α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors, thus leading to the
release of BDNF (Abdallah et al., 2015; Duman, 2014; Duman et al.,
2016). Recent studies reported that local BDNF protein synthesis at
synapses plays a critical role in the regulation of local spines and
dendrites morphology (Baj et al., 2011; Kellner et al., 2014; Song et al.,
2017). Transcription of BDNF is regulated by at least nine different
promoters, giving rise to different splice variant transcripts (Aid et al.,
2007), which were proposed to bear a spatial code for local translation
of BDNF (Baj et al., 2011). Indeed, splice variants containing transcripts
from exon 2 (BDNF-2) and 6 (BDNF-6) were shown to be trafficked to
distal dendrites, and suggested to play a key role in regulating local
dendritic morphology (Aid et al., 2007; Baj et al., 2011; Chiaruttini
et al., 2008; Kellner et al., 2014). Interestingly, both chronic treatment
with antidepressants and physical exercise have been shown to increase
trafficking of BDNF transcripts at distal dendrites (Baj et al., 2012).
However, at present, it is not known whether trafficking of BDNF
mRNA is regulated by stress or KET treatment.
In the present work, we show that in the Chronic Mild Stress (CMS)
model of depression anhedonic behavior, and the impairment of: (1)
glutamate presynaptic release; (2) BDNF mRNA dendritic trafficking
and (3) dendritic morphology in HPC, are restricted to stress-vulnerable
animals. Moreover, we show that a single administration of sub-anes-
thetic KET is able to restore behavior and these cellular/molecular al-
terations in vulnerable rats.
Fig. 1. (a) Experimental plan: animals were
subjected to a variable sequence of mild
stressors for five weeks. Sucrose preference
test (SPT) was performed to evaluate an-
hedonic behavior. KET or vehicle (VEH)
were acutely administered 24 h before sa-
crifice. (b) SPT of CNT and CMS rats at Day
+22 of CMS. n = CNT 101; CMS 188.
Unpaired t-test: **p < 0.001 vs CNT; (c)
Separation of resilient and vulnerable ani-
mals applying a cut-off at 55% of sucrose
preference at Day +22 of CMS. n = CNT
101; CMS-R 100; CMS-V 88. (d) SPT of CNT
and CMS rats at Day +35 of CMS, 24 h after
KET/VEH treatment n = CNT 59; CMS-R
53; CMS-V 27; CMS-V + KET 25. (e) Body
weight gain; n=CNT 101; CMS-R 100;
CMS-V 88. (f) Adrenal glands weight.
n = CNT 54; CMS-R 48; CMS-V 25; CMS-
V + KET 21. (g) CORT serum levels.
n = CNT 30; CMS-R 27; CMS-V 15; CMS-
V + KET 15. Data are shown as means ±
standard error of the mean. TPHT:
*p < 0.05 vs CNT; **p < 0.001 vs CNT;
#p < 0.05 vs CMS-R; ##p < 0.001 vs
CMS-R; §§p < 0.001 vs CMS-V.
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2. Material and methods
2.1. Animals
Experiments were performed in accordance with the European
Community Council Directive 2010/63/UE and approved by the Italian
legislation on animal experimentation (Decreto Legislativo 26/2014,
authorization N 308/2015-PR).
A total of 144 male Sprague-Dawley 150–175 g rats (Charles River,
Calco, Italy) were housed two per cage at 20–22 °C, 12 h light/dark
cycle (light on 7:00 a.m. off 7:00 p.m.), water and food ad libitum,
except when required for CMS.
2.2. Chronic mild stress
96 rats were exposed once or twice daily to random, mild and un-
predictable stressors for five weeks (Strekalova et al., 2011; Willner,
2017) (Fig. 1a). CMS included: up to 12 h of food or water deprivation,
overcrowding, social isolation, cage soiled with water in sawdust, 45°
cage tilting, light-on overnight, light/dark cycle reversal, 5 min of
forced swim.
2.3. Sucrose preference test
Two days before CMS, sucrose habituation was performed exposing
animals to two bottles containing 1% sucrose solution, for 2 h. Animals
were subjected to sucrose preference test (SPT) one day before CMS
(Day −1), after three weeks (Day +22), and 1 h before sacrifice (Day
+35) (Fig. 1a). SPT consisted in presenting rats with two bottles, one
containing 0.5% sucrose and one containing tap water, for 1 h. The
position of the bottles was inverted after 30min. Sucrose preference was
calculated as: [sucrose solution intake (ml)/total fluid intake (ml)]
x100] (Strekalova et al., 2011).
2.4. Drug treatment
24 h before sacrifice, rats were i.p. injected with racemic KET (MSD
Animal Health, Milan, Italy) (10mg/kg) or saline.
2.5. Analysis of phenotypic changes
Body weight gain was monitored twice a week. Adrenal/total body
weight ratio was calculated as: total weight of left and right adrenal
glands (mg)/body weight (g) (Ieraci et al., 2016). Serum corticosterone
levels were measured as in (Musazzi et al., 2017).
2.6. Preparation of purified synaptosomes and neurotransmitter release
experiments
Purification and superfusion of synaptic terminals (synaptosomes)
were performed as previously reported (Bonanno et al., 2005;
Bonifacino et al., 2016; Treccani et al., 2014). Synaptosomes were
freshly prepared from homogenized HPC of 8–12 animals/group, by
centrifugation on discontinuous Percoll gradients, and superfused with
a standard physiological medium (140mM NaCl, 3 mM KCl, 1.2mM
MgSO4, 1.2 mM CaCl2, 1.2 mM NaH2PO4, 5mM NaHCO3, 10mM glu-
cose, 10mM HEPES, pH 7.4). After 36min of superfusion, released
sample (representing basal neurotransmitter release) was collected for
3min (t= 36–39). To measure depolarization-dependent neuro-
transmitter overflow, a 90 s exposure of synaptosomes to KCl 15mM,
followed by 6min of collection of released sample (t= 39–45), was
used. Collected fractions were analyzed for endogenous glutamate and
GABA by HPLC (Bonanno et al., 2005; Bonifacino et al., 2016; Treccani
et al., 2014).
2.7. qPCR
Total RNA was extracted from HPC, using Direct-zol RNA MiniPrep
(Zymo Research, Freiburg, Germany), reverse-transcribed to cDNA with
iScript cDNA Reverse Transcription kit (BioRad Laboratories, Segrate,
Italy) and qPCR was performed with a 7900HT Fast PCR System
(Applied Biosystems, Monza, Italy) (Ieraci et al., 2016). List of primers
used for qPCR is reported in Supplementary Table S1.
2.8. BDNF ELISA
BDNF protein levels were measured from homogenized HPC of
13–14 animals/group, using the BDNF Emax® ImmunoAssay System
(Promega, Milan, Italy).
2.9. Riboprobes preparation for in situ hybridization
Digoxigenin (DIG)-labeled riboprobes detecting total BDNF, BDNF-2
or BDNF-6 transcripts were generated from PCR templates adapted with
SP6 and T7 RNA polymerase sites. Riboprobes were transcribed using a
DIG RNA Labeling Kit (Thermo Scientific) (Russo et al., 2013), purified
in NucAwayTM spin columns (Ambion, Monza, Italy) and quantified
with Nanodrop 1000 (Thermo Scientific).
2.10. In situ hybridization
After sacrifice, brains were fixed in 4% PFA solution for 24 h and
placed in 30% sucrose. Coronal slices (40 μm) were prepared and stored
in cryo-protectant sectioning buffer (30% ethylene glycol, 30% glycerol
and 0.05M phosphate buffer) at −20 °C.
In situ hybridization was developed using the Vectastain® Elite ABC-
Peroxidase Staining Kit (Vector Laboratories, Segrate, Italy) (La Via
et al., 2013). Free-floating sections were post-fixated for 3 h in 4% PFA
at RT, washed in 0.1 Tween 20 in PBS (PBST), and treated with 0.3%
H2O2. The slices were then permeabilized with 2.3% sodium meta-
periodate in H2O, and quickly washed in H2O. The sections were in-
cubated in 1% sodium borohydride in 0.1M Tris-HCl buffer pH 7.5, and
washed in PBST at RT. The slices were digested with 8 μg/ml proteinase
K in PBST for 20min and washed in PBST. After digestion, the tissue
slices were fixed in 4% PFA for 5min and washed in PBST at RT. Slices
were incubated at 55 °C for 90min in pre-hybridization solution con-
taining 20mM Tris-HCl (pH7.5), 1 mM EDTA, 1x Denhardt's solution,
300mM NaCl, 100mM DTT, 0.5 mg/ml salmon sperm DNA, 0.5mg/ml
polyadenylic acid, and 50% formamide. Slices were then incubated ON
at 55 °C in hybridization solution, composed of the prehybridization
solution supplemented with 10% dextransulfhate and 100 ng/ml DIG-
labeled riboprobes. The next day, the slices were washed in 2x saline
sodium citrate, 0.1% Tween 20 (SSCT), and 50% deionized formamide
at 55 °C for 30min, for 20min in 2x SSCT at 55 °C, and twice in 0.2 x
SSCT at 60 °C for 30min. Subsequently, the slices were detected using
the peroxidase method with biotinylated donkey anti-mouse IgG anti-
bodies and diaminobenzidine as chromogen (Vector Laboratories,
Segrate, MI, Italy).
The images of in situ hybridization experiments were acquired using
an LSM 510 Meta (Carl Zeiss Microscopy, Jena, Germany) microscope,
and the maximal distance of hybridization signal in dendrites (maximal
distance of dendritic labeling) was determined by AxionVision LE64
(Zeiss, Milano, Italy) using the function Measure Length. In particular,
the hybridization signal was measured starting from the origin of
dendrite from the cell body, to the point at which the in situ labeling
was no longer clearly distinguishable from the background.
Dendrites of pyramidal neurons in CA1 and CA3 hippocampal re-
gions have been analyzed; 3–4 rats/group, 2–3 slices/rat and 80–100
dendrites/slice were analyzed. All the experiments were coded and
analyzed in a blinded manner.
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2.11. Golgi staining and dendritic analysis
Immediately after sacrifice, left or right hemispheres were processed
for Golgi staining using the Rapid Golgi Stain Kit (FD
NeuroTechnologies, Inc., Columbia, MD, USA) (Nava et al., 2017).
Hemispheres were coronally sliced (200 μm) on a VT1200S vibratome
(Leica, Wetzlar, Germany). CA1 and CA3 areas of HPC were identified
on a BX50 light microscope (Olympus, Tokyo, Japan) using newCAST
software (Visiopharm, Hørsholm, Denmark). Z-stacks (1 μm per Z-step
size) of 5 CA1 or CA3 pyramidal neurons with untruncated branches
were acquired using a×60 oil objective. Collapsed Z-stacks were im-
ported in Bitplane Imaris software (version 7.7.1, Andor Technology
Ltd, Belfast, Northern Ireland) and dendrites were reconstructed using
the FilamentTracer function. Dendrite length and branching, and Sholl
analysis were assessed (Nava et al., 2017).
2.12. Statistical analysis
For SPT (Day −1, +22 and + 35), adrenal glands weight, CORT
serum levels, neurotransmitter release experiments, BDFN levels, and
dendritic analyses one-way ANOVA followed by the Tukey's post-hoc
test (TPHT) was used. For SPT (Day +22, considering CNT vs. CMS),
unpaired two-tailed Student t-test was used. For weight gain and Sholl
analysis, two-way ANOVA followed by TPHT was used. For in situ hy-
bridization of BDNF transcripts Multilevel Covariance Analysis (MCA)
was used, considering two random effects: rat and slice within rat.
Dendritic trafficking was modeled on log-scale; F values were computed
using Kenward-Roger degrees of freedom; p-values were adjusted for
multiple comparisons using single step procedure.
Data were expressed as mean ± standard error of the mean
(S.E.M.). Statistical analysis was carried out using GraphPad Prism6
(GraphPad Software, La Jolla, CA, USA) or R version 3.5.1 (R
Foundation).
3. Results
3.1. Sucrose preference test allows deeming rats resilient or vulnerable to
chronic mild stress. Ketamine rapidly restores anhedonic behavior in
vulnerable rats
The CMS group showed a significant reduction in sucrose preference
already after 3 weeks of stress (t=3.87) (Fig. 1b). Applying a 55% cut-
off (Strekalova et al., 2011), rats with a sucrose preference higher than
55% were considered resilient to CMS (CMS-R), while rats showing
preference lower than 55% were considered vulnerable (CMS-V)
(F2,144= 143.9, p < 0.001) (Fig. 1c). This was not due to preexisting
differences in preference for sucrose (Supplementary Fig. S1).
After 5 weeks of CMS, half of the CMS-V rats (n = 25) were injected
with KET (CMS-V-KET), and SPT was repeated 23 h later, 1 h before
sacrifice. We found that, while saline-treated CMS-V rats still showed
anhedonic behavior, sucrose preference was significantly increased in
CMS-V + KET compared to CMS-V, and restored at the level of CMS-R
rats (F3,104= 23.08, p < 0.001) (Fig. 1d). Previous work has shown
that subanesthetic KET has no effect on sucrose intake in naïve animals,
as opposed to animals subjected to CMS (Autry et al., 2011). Moreover,
in a separate set of animals, we found no effect of KET in SPT in CMS-R
rats (Supplementary Fig. S2). Taken together, these results show that
ketamine affects hedonic behavior only in animals subjected to chronic
stress.
3.2. Chronic mild stress induces major phenotypic changes in vulnerable
rats
Two-way ANOVA revealed a significant effect of CMS
(F2,1036= 264.7, p < 0.001), time (F11,1036= 151.8, p < 0.001) and
interaction between CMS and time (F22,1036= 8.17, p < 0.001) on
body weight gain (Fig. 1e). TPHT showed that, starting from Day +5 of
stress, CMS significantly decreased body weight gain in both CMS-R and
CMS-V in comparison to CNT. The decrease of weight gain was more
evident in CMS-V in comparison to CMS-R, with a difference that
reached significance between Day +19 and Day +26. No effect of KET
on body weight gain was detected at Day +35 (F3,23= 12.61,
p < 0.001) (Supplementary Fig. S3).
Weight of adrenal glands was increased in CMS-V, but not in CMS-R,
while KET had no significant effect on this readout (F3,144= 8.42,
p < 0.001) (Fig. 1f). CMS also increased serum CORT levels, although
the increase was significantly higher in CMS-V compared to CMS-R, and
again no effect of KET was revealed (F3,77= 21.52, p < 0.001)
(Fig. 1g).
3.3. Chronic mild stress reduces presynaptic release of glutamate and GABA
in hippocampus of vulnerable rats. Ketamine partly restores the changes
As stress is known to induce changes in glutamate/GABA release
and synaptic transmission, we measured the release of these two amino
acid neurotransmitters (Bonanno et al., 2005; Bonifacino et al., 2016;
Popoli et al., 2012). Both basal and depolarization-evoked release of
endogenous glutamate in CMS-R were similar to CNT (Fig. 2a and b).
CMS significantly reduced basal glutamate release from superfused
synaptosomes selectively in CMS-V animals, compared to both CNT and
CMS-R (F3,43=2.18, p < 0.05) (Fig. 2a). Interestingly, KET affected
only basal release in CMS-V, with a strong trend toward normalization,
and no significant differences between CMS-V + KET group and CNT or
CMS-R. Instead, depolarization-evoked release of glutamate was sig-
nificantly reduced in HPC synaptosomes from both CMS-V and CMS-
V + KET rats compared to CMS-R, suggesting no effect of KET at this
level (F3,43=4.00, p < 0.05) (Fig. 2b).
With regard to endogenous GABA release, the basal release was
found increased in CMS-R compared to CNT, CMS-V and CMS-V + KET
(F3,43=6.10, p < 0.05) (Fig. 2c). Conversely, we found that CMS
Fig. 2. (a) Basal glutamate release from HPC synaptosomes in superfusion.
n = CNT 14; CMS-R 16; CMS-V 7; CMS-V + KET 9. (b) 15 mM KCl-evoked
glutamate release from HPC synaptosomes in superfusion. n = CNT 11; CMS-R
16; CMS-V 6; CMS-V + KET 8. (c) Basal GABA release from HPC synaptosomes
in superfusion. n = CNT 18; CMS-R 21; CMS-V 10; CMS-V + KET 9. (d) 15 mM
KCl-evoked GABA release from HPC synaptosomes in superfusion. n = CNT 9;
CMS-R 13; CMS-V 6; CMS-V + KET 6. TPHT: *p < 0.05 vs CNT; **p < 0.001
vs CNT; #p < 0.05 vs CMS-R; ##p < 0.05 vs CMS-R; §p < 0.05 vs CMS-V.
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reduced the depolarization-evoked release of GABA selectively in CMS-
V compared to CNT, an effect that was fully restored to CNT levels by
KET (F3,43=2.58, p < 0.05) (Fig. 2d).
3.4. Chronic mild stress reduces the expression of BDNF mRNA and protein
in hippocampus. Ketamine does not restore the changes
Total BDNF mRNA levels in whole HPC were significantly reduced
by CMS in both CMS-V and CMS-R, and KET treatment had no effect
(F3,34= 8.72, p < 0.001) (Fig. 3a).
We also analyzed the effect of CMS and KET on the transcription of
BDNF splice variants BDNF-1, BDNF-2, BDNF-4 and BDNF-6, the major
splice variants expressed in rat brain (Aid et al., 2007). We found that
CMS caused a general reduction of the expression of BDNF transcripts in
all stressed rats. BDNF-1 mRNA levels were significantly reduced in
HPC of CMS-V and CMS-V + KET, but not in CMS-R rats (F3,34= 4.97,
p < 0.05) (Fig. 3a). BDNF-2 mRNA levels were significantly reduced in
CMS-R, CMS-V, and CMS-V + KET (F3,34=7.89, p < 0.001), and the
same was observed for BDNF-4 (F3,34=13.85, p < 0.001), and BDNF-
6 levels (F3,34=5.74, p < 0.05) (Fig. 3a). As for total BDNF, KET did
not restore the levels of the splice variants.
We also measured the BDNF protein expression levels in whole HPC
and found a significant increase of BDNF selectively in CMS-R
(F3,50=3.90, p < 0.05) (Fig. 3b). BDNF protein level of CMS-V (with
or without KET) was not different from controls.
3.5. Chronic mild stress reduces the dendritic trafficking of total BDNF
mRNA and BDNF splice variants in hippocampus of vulnerable rats.
Ketamine restores the changes
Local translation and release of BDNF at synapses, also dependent
on dendritic transcripts, has been suggested to be central for the rapid
antidepressant action of KET (Song et al., 2017). Therefore, we per-
formed in situ hybridization studies (Fig. 4a) to assess changes in BDNF
mRNA dendritic localization. A significant decrease in the trafficking of
total BDNF mRNA was found in the CA1 region of HPC of both CMS-R
and CMS-V (MCS,F4,16.88=5026, p < 0.001); this reduction was
greater in CMS-V compared to CMS-R and restored to the levels of CMS-
R by KET (Fig. 4b). Instead, in CA3 region, we found a significant de-
crease in the trafficking of total BDNF selectively in CMS-V
(MCS,F4,20.17=6135, p < 0.001); this impairment was completely
restored by KET (Fig. 4c).
We also analyzed the effect of CMS and KET on the trafficking of
BDNF splice variants containing BDNF-2 or -6, the main BDNF tran-
scripts transported to distal dendrites (Baj et al., 2011). In CA1, BDNF-2
dendritic trafficking was increased in CMS-R, while decreased in CMS-V
rats (MCS,F4,20.58=3042, p < 0.001); KET treatment completely re-
stored this change in CMS-V (Fig. 4d). Similar results were obtained in
CA3 (MCS,F4,13.57=337, p < 0.001): BDNF-2 dendritic trafficking
was increased in CMS-R, while decreased in CMS-V and restored to CNT
levels by KET (Fig. 4e).
Concerning BDNF-6 mRNA, in CA1 its dendritic trafficking was in-
creased in CMS-R and reduced in CMS-V; no effect of KET was detected
(MCS,F4,15.92=5660, p < 0.001) (Fig. 4f). In CA3, BDNF-6 trafficking
was reduced selectively in CMS-V; KET fully reversed this change
(MCS,F4,7.85=5461, p < 0.001) (Fig. 4g).
3.6. Chronic mild stress induces retraction of CA3 apical dendrites in
hippocampus of vulnerable rats. Ketamine restores the changes
In CA1 we found no significant changes in length and branching of
apical and basal dendrites, as confirmed by Sholl analysis
(Supplementary Fig. S4).
Conversely, one-way ANOVA revealed that CMS significantly re-
duced the total length of apical dendrites in the CA3 of CMS-V
(F3,38= 5.67, p < 0.05) (Fig. 5a). This effect was completely restored
to control levels by KET. Moreover, CMS induced dendritic simplifica-
tion selectively in CMS-V rats, as shown by the reduction of the total
number of branches of CA3 apical dendrites, which was completely
restored by KET (F3,38= 5.52, p < 0.05) (Fig. 5b). We found no sig-
nificant difference between experimental groups in the total length
(Fig. 5c) and branching number (Fig. 5d) of basal dendrites.
Sholl analysis confirmed the CMS-induced retraction of apical
dendrites in the CA3 of CMS-V (F3,90= 10.89, p < 0.001). In parti-
cular, TPHT showed that CMS significantly decreased the number of
intersections of distal apical dendrites (between 300 μm and 380 μm),
selectively in the CA3 of CMS-V; KET rescued this effect in CMS-V
(Fig. 5e). Instead, Sholl analysis showed no significant effect of CMS in
basal dendrites (Fig. 5f).
4. Discussion
In this work we employed one of the most popular and reliable
protocols of chronic stress, the CMS model (Willner, 2017), to analyze
the stress-induced behavioral, cellular and molecular changes involved,
and to understand what changes are restored by the single adminis-
tration of a sub-anesthetic dose of the rapid-acting antidepressant KET.
In most previous studies, the effects of KET were investigated in groups
of stressed animals taken as a whole (Li et al., 2011; Ma et al., 2013;
Papp et al., 2017; Sun et al., 2016). Here we distinguished resilient and
vulnerable animals by using the SPT and, for the first time, investigated
the effects of KET in the animals vulnerable to CMS.
After CMS, we observed a number of changes exclusive for vulner-
able rats, namely: (1) anhedonic behavior; (2) hyperactivation of the
HPA axis (adrenal gland weight and CORT level); (3) reduction of
basal/depolarization-evoked glutamate release and evoked GABA re-
lease in HPC; (4) reduction of dendritic BDNF mRNA trafficking; (5)
atrophy/remodeling of apical dendrites. Reduction of expression of
total BDNF mRNA and BDNF splice variants was found in both resilient
and vulnerable rats. Most of these putative maladaptive changes were
completely restored by the KET treatment after 24 h, considered the
peak of the rapid antidepressant effect of KET (Abdallah et al., 2015;
Fig. 3. (a) Levels of total BDNF transcripts and of BDNF splice variant transcripts containing exon 1 (BDNF-1), 2 (BDNF-2), 4 (BDNF-4) or 6 (BDNF-6) in HPC
homogenate. n = CNT 8; CMS-R 9; CMS-V 10; CMS-V + KET 10. (b) BDNF protein levels in HPC homogenate. n = CNT 13; CMS-R 13; CMS-V 14; CMS-V + KET 14.
TPHT: *p < 0.05 vs CNT; **p < 0.001 vs CNT; #p < 0.05 vs CMS-R.
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Duman, 2014), with the exception of HPA axis hyperactivation, evoked
glutamate release and expression of BDNF in HPC. The rapid restoration
of neuroarchitecture compromised by stress was shown here for the first
time in the HPC of CMS-V rats.
In our hands, HPA axis hyperactivation does not seem to be a target
of KET, which suggests that KET targets are downstream of this readout,
as found previously for traditional antidepressants (Musazzi et al.,
2010). As for glutamate/GABA release there is little or no previous data
in the literature.
4.1. The impairment in glutamate and GABA release induced by CMS is
partly restored by ketamine
A novel result of this work is the finding that CMS induces a major
impairment of presynaptic release of endogenous glutamate in the HPC,
only in CMS-V rats (see Fig. 2). Dysfunction of the glutamate system, a
major outcome of stress in HPC and cortical areas, is considered a main
feature of neuropsychiatric pathophysiology (Duman and Aghajanian,
2012; Lener et al., 2017; Murrough et al., 2017; Musazzi et al., 2017,
2010; Sanacora et al., 2012). The present findings are in line with
previous studies showing that chronic stress reduces excitatory trans-
mission in HPC and cortical areas (Kallarackal et al., 2013; Marrocco
et al., 2014; Yuen et al., 2012). There is a general consensus in the
literature on the hypothesis that dysfunction of excitatory transmission
(reduction in HPC and in parts of the PFC) is a reason for impaired top-
down control of subcortical areas, such as reward circuitry and amyg-
dala, implicated in anhedonia, lowered mood and dysregulation of
emotional control, typical of MDD (Price and Drevets, 2010; Workman
et al., 2018). Strong support for this hypothesis comes from the com-
pelling evidence of volumetric changes in these brain areas and of
changes in functional connectivity in MDD patients (Abdallah et al.,
2017). It is conceivable that the maladaptive changes in neuroarchi-
tecture, extensively described after chronic stress, are accompanied by
a reduction of glutamate release and impairment of synaptic home-
ostasis. Homeostatic synaptic mechanisms restore stability to brain
circuitry in response to long-term changes in neuronal activity
(Turrigiano, 2012); impairment of these mechanisms is likely to be
involved in pathophysiology, whereas manipulation of homeostatic
plasticity could be necessary for therapeutic action (Workman et al.,
2018). Intriguingly, we found that KET seems to affect only basal but
not depolarization-evoked glutamate release in CMS-V rats. Although at
present it is unknown how this selective action of KET is connected to
its antidepressant effect, it is interesting that basal glutamate release at
synapses is a key regulator of homeostatic plasticity through local
protein synthesis (Kavalali, 2015).
With regard to endogenous release of GABA, we found that basal
release, similar to CNT in CMS-V, was enhanced in resilient rats, while
depolarization-evoked GABA release was impaired in CMS-V rats and
completely restored by KET treatment. Previous work has shown that
CMS reduces the number of GABAergic interneurons in HPC, while
impairing GABA synthesis, uptake and inhibitory synaptic transmission
in PFC (Czéh et al., 2015; Wang et al., 2016). Interestingly, a higher
number of GABAergic interneurons has been found in the PFC of re-
silient rats (Varga et al., 2017). Instead, the enhancement of basal
GABA release induced by KET cannot be ascribed to a change in the
number of interneurons and is likely due to changes in the parameters
of GABA release. Our finding that KET completely restores evoked re-
lease of GABA in the HPC of CMS-V rats adds to its action on glutamate
release and suggests a more complex action of KET on synaptic dys-
function and excitation/inhibition balance.
4.2. The impairment in dendritic BDNF trafficking induced by CMS is
completely restored by ketamine
While the reduction of BDNF expression after CMS was expected,
the complete lack of effect of KET on this deficiency was somewhat a
surprise. Also, it was intriguing to find a higher BDNF protein expres-
sion in CMS-R rats, which is in line with the idea that resilience to stress
is not a simple reversal of vulnerability mechanisms and involves pro-
adaptive neuroplasticity (Musazzi et al., 2017; Russo et al., 2012).
Recent studies have shed more light on some aspects of BDNF synthesis
and release at synapses, and on their involvement in MDD pathophy-
siology and rapid-antidepressant action of KET (Song et al., 2017) and
refs. therein). First, hybridization studies have reliably detected en-
dogenous BDNF mRNA in neuronal dendrites (in both cell cultures and
brain). Second, functional studies have shown that dendritic BDNF
Fig. 4. (a) Representative images of in situ hybridization of total BDNF mRNA
in CA1 and CA3 regions of HPC in CNT, CMS-R, CMS-V and CMS-V + KET rats.
(b) Dendritic trafficking of total BDNF transcripts in CA1. (c) Dendritic traf-
ficking of total BDNF transcripts in CA3. (d) Dendritic trafficking of BDNF
splice variant transcripts containing exon 2 (BDNF-2) in CA1. (e) Dendritic
trafficking of BDNF splice variant transcripts containing exon 2 (BDNF-2) in
CA3. (f) Dendritic trafficking of BDNF splice variant transcripts containing exon
6 (BDNF-6) in CA1. (g) Dendritic trafficking of BDNF splice variant transcripts
containing exon 6 (BDNF-6) in CA3. n = 3–4 rats/group, 2–3 slices/rat, 80–100
dendrites/slice. MCA: **p < 0.001 vs CNT; ##p < 0.001 vs CMS-R;
§§p < 0.001 vs CMS-V.
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release is required for certain synaptic events, including enhancement
of glutamate release and homeostatic synaptic plasticity, while dis-
ruption of dendritic BDNF localization leads to deficiencies in synaptic
function. As a consequence, the purported role of BDNF in the rapid
action of KET (Autry and Monteggia, 2012; Li et al., 2011) could be
linked to selective and rapid trafficking, synthesis and release of den-
dritic pools of BDNF. This mechanism could be common to other glu-
tamatergic rapid-acting antidepressants, and may be the basis of a fu-
ture strategy for antidepressant drug development (Song et al., 2017).
In light of these aspects, the present novel findings that CMS induces
impairment of BDNF trafficking into dendrites, and KET rapidly restores
this critical supply, may open new paths to understand better the role of
BDNF in MDD pathophysiology and therapy. It is interesting that the
reduction of BDNF trafficking implicates the two splice variants (BDNF-
2 and BDNF-6) previously shown to be transported to distal dendrites
(Baj et al., 2012, 2011). Intriguingly, the action of KET here seems to
distinguish between BDNF-2 (whose translocation is restored in both
CA1 and CA3) and BDNF-6 (restored only in CA3). It has been shown
that BDNF contributes to the homeostatic plasticity of neuronal firing
rates (Rutherford et al., 1998). Stabilization of homeostatic plasticity,
compromised in MDD pathophysiology by chronic stress and other
factors, has been purported as a major aspect of therapy, whether by
pharmacological treatments or other means (Workman et al., 2018).
Different mechanisms have been proposed for the action of keta-
mine, including NMDA receptor-independent mechanisms (see Zanos
et al., 2016; Williams et al., 2018; Wray et al., 2018; Zanos et al., 2018;
Kadriu et al., 2019). Current hypotheses on the nature of rapid anti-
depressant mechanism of KET include rapid increase of glutamate re-
lease and rapid translation/release of BDNF at excitatory synapses
(Autry and Monteggia, 2012; Li et al., 2011). However, it is not clear if
the surge of glutamate release induces BDNF rapid translation or vice
versa. It is likely that the two phenomena are related, but how?
There is convergent evidence in the literature that neuronal acti-
vation can lead to detectable increases of mRNAs in dendrites, in-
cluding BDNF. Indeed, activation of selected synapses by glutamate
uncaging can drive changes in the localization and local translation of
endogenous mRNA in dendrites of HPC neurons (Yoon et al., 2016). On
the other hand, BDNF may orchestrate presynaptic changes in a state-
dependent manner. It has been shown that blockade of AMPA receptors
in cultured HPC neurons induces rapid enhancement of presynaptic
function, requiring synthesis and release of BDNF, locally translated in
dendrites, as a retrograde messenger (Jakawich et al., 2010). Thus,
changes of glutamate release and BDNF could be interconnected in the
rapid action of KET. Future studies are bound to shed more light on the
involvement of these aspects in rapid antidepressant action.
Fig. 5. (a) Total dendritic length of CA3 apical dendrites. (b) Branching number of CA3 apical dendrites. (c) Total dendritic length of CA3 basal dendrites. (d)
Branching number of CA3 basal dendrites. (e) Sholl analysis of CA3 apical dendrites. (f) Sholl analysis of CA3 basal dendrites. n = CNT 11; CMS-R 11; CMS-V 10;
CMS-V + KET 10. TPHT: *p < 0.05 vs CNT; #p < 0.05 vs CMS-R; §p < 0.05 vs CMS-V. (g) Representative drawings of CA3 pyramidal neurons reconstructed with
Imaris software.
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5. Conclusions
In conclusion, we have shown that KET rapidly reverses anhedonic
behavior in rats vulnerable to CMS, and this is paralleled by partial
restoration of glutamate/GABA release in the HPC, complete restora-
tion of BDNF dendritic trafficking and of apical dendrites atrophy.
Therefore, this work suggests a relationship between vulnerability/re-
silience to chronic stress, glutamate/GABA release and availability of
BDNF mRNA at synapses. Overall, the present results are consistent
with a mechanism of ketamine involving restoration of synaptic
homeostasis, through re-equilibration of glutamate/GABA release and
dendritic BDNF for synaptic translation and reversal of synaptic and
circuitry impairment.
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